×
About 253 results

ALLMedicine™ Acute Graft Versus Host Disease Center

Research & Reviews  97 results

An investigation of the diagnostic, predictive, and prognostic impacts of three colonic...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389423
PloS One; Kreft A, Hippe K et. al.

Aug 27th, 2021 - Acute graft versus host disease (aGvHD) is an important, life-threatening complication after allogeneic hematopoietic stem cell transplantation (alloHSCT). To investigate the value of multiple simultaneous colon biopsies in improving diagnostic ac...

IFNG-AS1 and MAF4 long non-coding RNAs are upregulated in acute leukemia patients who u...
https://doi.org/10.1016/j.retram.2021.103307
Current Research in Translational Medicine; Jafari L, Izadirad M et. al.

Aug 12th, 2021 - Acute graft versus host disease (aGVHD) is an immune-mediated reaction that results in impaired immune and body function after allogeneic hematopoietic stem cell transplantation (allo-HSCT). lncRNAs have been discovered as particular T cell regula...

Genetic susceptibility to acute graft versus host disease in pediatric patients undergo...
https://doi.org/10.1038/s41409-021-01386-8 10.1182/blood-2010-01-261958 10.1200/JCO.2004.02.189 10.1038/bmt.2010.174 10.1056/NEJMra1609337 10.1182/bloodadvances.2017011502 10.1016/S0140-6736(09)60237-3 10.1155/2012/257086 10.1182/blood-2016-09-737700 10.1097/TP.0b013e3182708e7c 10.18632/oncotarget.20310 10.1016/j.bbmt.2019.11.026 10.1182/blood-2015-09-669846 10.1038/nature15393 10.1038/nprot.2009.86 10.1086/519795 10.1038/bmt.2012.244 10.1006/abio.1999.4293 10.2174/1389200215666140202214012 10.1182/blood-2017-11-817973 10.1038/sigtrans.2017.23 10.1111/bjh.13959 10.1126/science.1098387 10.1038/nature08467 10.1007/s00277-020-03935-5 10.1007/s10549-015-3368-5 10.1002/humu.21641 10.1111/ahg.12293 10.1093/brain/awu408 10.1038/srep18475 10.4049/jimmunol.179.1.647 10.3389/fimmu.2012.00118 10.1038/nature24277 10.1038/onc.2013.587 10.1038/leu.2013.206 10.1161/CIRCULATIONAHA.113.001720 10.1016/j.beha.2008.02.003 10.1016/j.beha.2008.02.002 10.1111/bjh.15456 10.1038/nri2327 10.1182/blood-2013-08-519157 10.1111/j.1365-2443.2011.01529.x 10.4049/jimmunol.1500531 10.1182/blood-2013-11-536888 10.1261/rna.747607 10.1261/rna.075416.120 10.1111/gbb.12127 10.1111/iji.12051 10.1046/j.1365-2141.2003.04676.x 10.1128/MCB.00480-14
Bone Marrow Transplantation; Ansari M, Petrykey K et. al.

Jul 4th, 2021 - The most frequent complication of allogeneic hematopoietic stem cell transplantation is acute Graft versus Host Disease (aGVHD). Proliferation and differentiation of donor T cells initiate inflammatory response affecting the skin, liver, and gastr...

Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogen...
https://doi.org/10.1111/petr.14041
Pediatric Transplantation; Wright M, Rangarajan H et. al.

May 21st, 2021 - Immunosuppressive prophylaxis is usually given to decrease the development of acute graft versus host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Belatacept is a Cytotoxic T-lymphocyte-associated protein 4, bloc...

see more →

News  4 results

Genomic Era Reaches Pediatric Oncology
https://www.onclive.com/view/genomic-era-reaches-pediatric-oncology

Dec 5th, 2020 - Rajen Mody, MBBS The relative rarity of pediatric cancers has hampered the work of uncovering their causes and developing new therapies, but efforts to expand the use of genomic and biomarker testing are beginning to provide new options for child...

FDA Sets Review Date for Remestemcel-L for Steroid-Refractory Pediatric Acute GVHD
https://www.onclive.com/view/fda-sets-review-date-for-remestemcel-l-for-steroid-refractory-pediatric-acute-gvhd

Jul 21st, 2020 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) has scheduled a date to review data supporting the biologics license application (BLA) for remestemcel-L (Ryoncil) as a treatment for children with steroid-refractory acute graft versus host dise...

Morning Break: Teva Pays for Opioid Crisis; Burnout A Real Diagnosis; 60 New Measles Cases
https://www.medpagetoday.com/primarycare/generalprimarycare/80082

May 28th, 2019 - Note that some links may require subscriptions. Teva Pharmaceuticals agreed to an $85 million settlement with Oklahoma over an alleged role in the state's opioid crisis -- which the company denied. (CNN) Incyte announced the FDA expanded indicatio...

Mesoblast stem cell therapy meets goal of pediatric Graft vs. Host study
https://www.reuters.com/article/us-mesoblast-study/mesoblast-stem-cell-therapy-meets-goal-of-pediatric-graft-vs-host-study-idUSKCN1G52W2

Feb 21st, 2018 - (Reuters) - Nearly 70 percent of children with potentially fatal acute Graft Versus Host Disease responded to treatment with an experimental stem cell therapy from Mesoblast Ltd, meeting the primary goal of a late-stage U.S. trial, the Australian ...

see more →